#3-50E. Delaying Rheumatoid Arthritis: Long-term Insights from the ALTO Trial (Lancet Rheumatol, 2026)

Can we alter the natural history of rheumatoid arthritis (RA) during the pre-clinical phase? Today we discuss the ALTO study, a long-term follow-up of the APIPPRA trial, which investigated whether a one-year course of abatacept could prevent RA in high-risk, ACPA-positive individuals with arthralgia. The study reveals that abatacept treatment significantly delayed the onset of clinical synovitis for up to four years compared to placebo. Crucially, the authors identified a specific "high-risk" phenotype—patients with a broad autoantibody profile—who were not only most likely to progress but also showed the most robust response to therapy. However, when critically appraising these findings, one must consider that the arthritis-free survival curves eventually converged, suggesting the intervention delays rather than permanently prevents disease, and that a specific data collection gap existed between the primary trial and this extension which relied on retrospective records. For rheumatologists, this study is pivotal as it validates the concept of disease interception while highlighting the urgent need for refined risk stratification to identify patients who will truly benefit from early immunomodulation.

Citation: Cope AP, et al. Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2026. DOI: 10.1016/S2665-9913(25)00371-6

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.